Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke (AIS)

Published: December 22, 2015

  • While numerous studies and registry data affirm the effectiveness of IV alteplase in AIS, only a minority (3-5%) of patients receive the drug.
  • Many of the current exclusions for alteplase are controversial to many stroke experts, with many considering them to be relative or absolute.
  • This statement is meant to be adjunctive to the 2013 Acute Ischemic stroke Guidelines.